This contract opportunity involves the establishment of non-exclusive discount contracts for the medication Rivaroxaban, specifically for film-coated tablets excluding the 2.5 mg strength. The contracts will be in effect from October 1, 2025, to September 30, 2027, with the option for suppliers to e
342 days left to bid. Opened 1 years ago, deadline 31 Jul 2027.
The AOK Rheinland-Pfalz/Saarland - The Health Fund is issuing a framework agreement for "Seating Furniture" consisting of a total of 4 lots. This specific tender is for Lot 3, which involves establishing a framework agreement for the purchase, delivery to the designated location, assembly/installati
The Open-House procedure for pharmaceutical discount contracts involving the active ingredient Pazopanib (ATC L01EX03), identified by the code "484904-2024", will be terminated effective January 31, 2026. Existing contracts will be canceled at that time, and no new contracts can be concluded under t
This contract opportunity involves the establishment of non-exclusive discount contracts for the medication Glatiramer Acetate, specifically for pre-filled syringes. The contracts will be in effect from February 1, 2026, to January 31, 2028, with the option for suppliers to enter into contracts at a
This contract opportunity involves the establishment of non-exclusive discount contracts for the pharmaceutical products Naproxen and Esomeprazole, in accordance with German social law. The contracts will be valid from February 1, 2026, to January 31, 2028, and suppliers can enter into contracts at
Innovate UK is investing up to £25.4 million to help develop and test early cancer diagnostic technologies, particularly for less common cancers, with projects costing £1.5-£4 million over 24-36 months.
Innovate UK is offering up to £25.4 million to fund collaborative projects that clinically validate innovative early cancer diagnostic technologies and devices led by UK organisations including at least one SME.
GHFT seeks echocardiography service providers to reduce diagnostic waiting times through a two-year contract with optional extensions starting April 2027.
St Helens Council is soft market testing for providers to deliver the Healthy Child Programme (health visiting and school nursing for ages 0-19), with an anticipated annual value of £4.2m over 5 years plus optional extensions.
